Issue 4, 2012

Design of multivalent galactosyl carborane as a targeting specific agent for potential application to boron neutron capture therapy

Abstract

A multivalent galactosyl carborane derivative 10 (dendritic glyco-borane, DGB) was synthesized and demonstrated as a potential cell-targeting agent in BNCT with HepG2 cells. DGB 10 improved the delivery of boron to HepG2 cells and neutron irradiation data show DGB 10 with ten-fold improvement at killing the HepG2 cells over BSH.

Graphical abstract: Design of multivalent galactosyl carborane as a targeting specific agent for potential application to boron neutron capture therapy

Supplementary files

Article information

Article type
Communication
Submitted
21 júl. 2011
Accepted
07 nóv. 2011
First published
23 nóv. 2011

Chem. Commun., 2012,48, 612-614

Design of multivalent galactosyl carborane as a targeting specific agent for potential application to boron neutron capture therapy

C. Lai, Y. Lin, F. Chou, C. Liang, E. Lin, Y. Chuang and C. Lin, Chem. Commun., 2012, 48, 612 DOI: 10.1039/C1CC14447B

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements